Physician

Vinai Kumar Katragadda, M.D., MHA

According to 2025 Medicare claims, Vinai Katragadda, M.D., MHA (NPI: 1679835441) practices nephrology in the Clarksville, TN-KY market, with the plurality of this provider's patient population coming from Montgomery, TN. This provider's primary affiliated billing organization is NEPHROLOGY ASSOCIATES, PC (NPI: 1700878360; TIN: 621239604) and primary practice location at 37209-3669.

Katragadda's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 769 traditional Medicare patients, billed 3,369 HCPCS/CPT codes, and received $236,165 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,881 prescription claims across 363 beneficiaries totaling $625,081 in drug costs, led by Farxiga (Dapagliflozin Propanediol). 2022 DME data shows 34 claims. Open Payments data shows 32 records totaling $615. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $95,962 and ending at $236,165. Concurrently, Part D prescription costs have risen steadily, from $63,940 to $625,081. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	331	1,026	$95,962
2018	684	3,020	$278,297
2019	834	3,751	$345,243
2020	707	2,859	$270,233
2021	501	1,921	$184,573
2022	509	1,663	$171,049
2023	818	3,348	$371,300
2024	769	3,369	$236,165

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	45	576	$63,940
2016	15	55	$2,644
2017	119	385	$37,117
2018	218	1,428	$160,885
2019	261	1,926	$207,287
2020	261	1,703	$165,468
2021	236	1,022	$81,273
2022	242	901	$119,414
2023	407	1,789	$672,519
2024	363	1,881	$625,081

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	11	$256
2022	N/R	34	$3,231
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	91	95	$114
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	87	163	$77
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	373	743	$56
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	186	462	$52
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	365	700	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	283	15,743	$275,135
Jardiance	Empagliflozin	124	7,428	$140,829
Lokelma	Sodium Zirconium Cyclosilicate	60	2,745	$38,858
Veltassa	Patiromer Calcium Sorbitex	26	1,498	$37,143
Auryxia	Ferric Citrate	17	436	$28,419

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	32	$615	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vinai Kumar Katragadda, M.D., MHA?

Tedicare shows public-source Medicare data for Vinai Kumar Katragadda, M.D., MHA (NPI 1679835441), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vinai Kumar Katragadda, M.D., MHA have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Vinai Kumar Katragadda, M.D., MHA?

Vinai Kumar Katragadda, M.D., MHA is linked to NEPHROLOGY ASSOCIATES, PC (billing NPI 1700878360) in the available physician profile data.

Does Vinai Kumar Katragadda, M.D., MHA have Open Payments data?

Vinai Kumar Katragadda, M.D., MHA has 32 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.